KA
VBIV icon

Klingman & Associates’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Klingman & Associates’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-163
Closed -$19K – 392
2016
Q2 		$19K Buy
+163
New +$16.3K 0.01% 265

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
TFCP
Twin Focus Capital Partners Boston, Massachusetts $983M AUM 37.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Klingman & Associates's VBIV Position: Q3 2016 in Review

Klingman & Associates sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2016, closing a stake of 163 shares — an estimated $19K sold.

Klingman & Associates first reported a position in VBIV in Q2 2016 and held it in 1 quarter. The position peaked at $19K in Q2 2016. 20 funds tracked by Wall St. Rank hold VBIV as of Q3 2016.

  • Klingman & Associates reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2016 after selling out during the quarter.
  • Klingman & Associates sold 163 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2016, an estimated $19K.
  • Klingman & Associates first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2016 and held it in 1 quarter.
  • Klingman & Associates's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $19K in Q2 2016.
  • 20 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2016.

Based on Klingman & Associates's 13F filing for Q3 2016, filed 19 Oct 2016.